RELENZA 5 mg/dosis POLVO PARA INHALACIÓN (UNIDOSIS)

USDailyMed:Zanamivir AU:B1 J05AH01(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-only (2R,3R,4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid 139110-80-8Y 60855 DB00558Y 54842Y L6O3XI777I D00902Y CHEBI:50663Y ChEMBL222813Y ZMR (PDBe,RCSB PDB) DTXSID0023749 Interactive image O=C(O)C=1O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](/N=C(\N)N)C=1 InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1YKey:ARAIBEBZBOPLMB-UFGQHTETSA-NY Zanamivir, sold under the brand nameRelenzaamong others, is ananti-viral medicationused to treat and preventinfluenzacaused byinfluenza Aandinfluenza B viruses. It is aneuraminidase inhibitorand was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo Wellcome in 1990and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B.Zanamivir is the first neuraminidase inhibitor commercially developed.It was developed byGlaxoSmithKline.